History of Santen
2001 - Current
| 2001 | Santen acquires the U.S. firm Advanced Vision Science, Inc.  Detantol, a treatment for glaucoma and ocular hypertension, Livostin, and anti-allergy ophthalmic solution, launched in Japan |
|---|---|
| 2002 |  Santen Holdings U. S. Inc. established Introduced the Dimple Bottle, newly developed for higher usability, distinguishability and productivitySante de U plus E alfa, Sante 40V and Sante 40 launched in Japan |
| 2003 | 2003-2005 Medium-term Management Plan (PDF: 142KB)PDF file.Page will open in a new window. devised Noto plant received ISO14001 certificationClariFlex foldable intraocular lenses launched in Japan |
| 2004 | U.S. sales partnership with Johnson & Johnson Vision Care, Inc. (currently VISTAKON pharmaceuticals, LLC) started Rescula, a treatment for glaucoma and ocular hypertension, launched in JapanAnti-rheumatic Metlate launched in Japan |
| 2005 | Santen Pharmaceutical (China) Co., Ltd. established |
| 2006 | Takakazu Morita is appointed chairman Akira Kurokawa is appointed president2006-2010 Medium-term Management Plan (PDF: 535KB)PDF file.Page will open in a new window. devised PAPILOCK Mini ophthalmic solution 0.1%, a treatment for vernal keratoconjunctivitis, launched in Japan Sante Medical 10 and Sante AL Cool II launched in Japan |
| 2007 |  Suzhou Plant established in China Sante Uruoi Contact a launched in Japan |
| 2008 |  Completion of pharmaceutical development facility and ancillary building at Nara Research and Development Center Santen launches Tapros, a treatment for glaucoma and ocular hypertensionTapros is the fruit of Santen’s first global development project spanning Japan, the U.S., Europe and Asia. The product is currently being sold in Japan as well as countries in Europe and Asia, and is gaining attention in ophthalmic markets in Japan and around the world as a new type of drug that fulfills unmet needs in the glaucoma treatment domain.  Eternity foldable intraocular lens launched in JapanSanten 40i launched in Japan Sante Lutax, nutritional supplement launched in Japan |
| 2009 | Santen Pharmaceutical (China) Co., Ltd. commenced marketing Sante FX V Plus launched in Japan |
| 2010 |
Long-term strategic vision toward 2020 Vision 2020 created Santen Pharmaceutical Korea Co., Ltd. commenced marketing Cosopt, a treatment of glaucoma and ocular hypertension, launched in Japan Diquas, a treatment for dry eye syndrome, launched |
| 2011 | 2011-2013 Medium-Term Management Plan (PDF: 297KB)PDF file.Page will open in a new window. formulated Accuject injector launched for inserting intraocular lenses Santen acquires Novagali Pharma S.A.S. and makes it a wholly owned subsidiary |
| 2012 | Santen Holdings EU B.V. established as a holding company Started integrated production at the Suzhou Plant VEGF inhibitor EYLEA solution for intravitreal injection launched for the treatment of patients with wet age-related macular degeneration. Pharmaceutical information is offered together with Bayer Yakuhin, Ltd. Sante Medical Guard and Sante 40 series launched |
| 2013 | Head Office transferred to Kita-ku, Osaka Ho Chi Minh Representative Office establishedSanten Pharmaceutical Asia Pte.Ltd. established in Singapore TAPROS MINI, a treatment of glaucoma and ocular hypertension, launched in Japan  Alesion, a treatment of allergic conjunctivitis, launched in Japan Eternity Natural Uni R foldable intraocular lens launched in Japan Sante Beautéye, Sante PC, Sante Kaiteki 40 and Sante Aln launched in Japan |
| 2014 | 2014-2017 Medium-Term Management Plan (PDF: 1.59MB)PDF file.Page will open in a new window. formulated Took over ophthalmology assets from U.S.-based Merck & Co., Inc.Established subsidiaries in Switzerland, Italy, the U.K., Spain, Thailand, Malaysia and the Philippines  Launch of TAPCOM (tafluprost/timolol maleate), a treatment for glaucoma and ocular hypertensionLaunch of Soft Santear Hitomi Stretch |
| 2015 | Santen Leadership Competencies introduced Assigned anti-rheumatic pharmaceuticals business to AYUMI Pharmaceutical Corporation Launch of COSOPT Mini, a treatment for glaucoma and ocular hypertension Launch of Ikervis, a treatment for severe keratitis in adult patients with dry eye disease Launch of New Sante de U α Launch of nutritional supplement Sante Lutax 20 + Vitamin & Mineral “IT General Award” received at the 2015 (33rd) Information Technology Award from the Japan Institute of Information Technology |
| 2016 | Established Santen Business Services Co., Ltd. Established Santen Eye Care Co., Ltd.Established SANTEN PHARMACEUTICAL (HONG KONG) LIMITED Acquired InnFocus Established Chongqing Santen Kerui Pharmaceutical Co., Ltd. Launch of Sante Medical 12, Sante Medical Guard EX and Sante Medical Active “IR Special Award” received for its investor relations activities from the Japan Investor Relations Association |
| 2017 | SANTEN LIMITED LIABILITY COMPANY in Russia established Eternity Natural Uni R foldable intraocular lens launched in JapanSante Beautéye contact launched in Japan Santen Selected as a Member of Dow Jones Sustainability Asia Pacific Index, an Index for Socially Responsible Investment Santen begins participation in UN Global Compact |
| 2018 | Akira Kurokawa is appointed chairman Medium-term Management Plan (MTP2020) (PDF: 1.51MB)PDF file.Page will open in a new window. formulated Entered into Drug Discovery and Development Agreement with PeptiDream EYBELIS, Glaucoma and Ocular Hypertension Treatment launched in Japan Sante Beautéye Mooncare launched in Japan Santen Awarded for “Corporate Governance of the year 2017” by the Japan Association of Corporate Directors |
| 2019 | Santen Canada Inc. in Canada established Entered into R&D collaboration and Option & Licence Agreement with Oxford Biomedica for development of gene therapy vectors for inherited retinal disease Entered into joint sales contact with Mitsubishi Tanabe Pharma concerning Alesion and Alesion LX Alesion LX Ophthalmic Solution 0.1%, anti-allergenic ophthalmic solution launched in Japan. LENTIS Comfort, Low-Add Segmental Intraocular Lens for Cataract Treatment launched in Japan Sante Medical Antibacterial and Sante PC Contact launched in Japan |
| 2020 | Announced (Formulation of) New Long-term Vision (PDF: 574KB)PDF file.Page will open in a new window. Aiming to Resolve Social Issues Related to the Eye Health of People around the WorldSanten China Investment Co., Ltd. established Entered into Partnership Agreement with International Telecommunication Union (ITU) Supporting ITU and WHO initiative 'Be He@lthy, Be Mobile' in Ophthalmology Announced Establishment of Joint Venture with Verily to Develop and Commercialize Unique Ophthalmic Devices Entered into an Exclusive Licensing Contract with jCyte in Japan, Asia and Europe for the jCell Therapy Program for Retinitis Pigmentosa Entered into a Strategic Alliance with Plano to Tackle the Global Burden of Myopia Entered into an Exclusive License Agreement with RVL Pharmaceuticals, Inc., an Osmotica Company, in Japan, Asia, and EMEA for RVL-1201, Treatment for Acquired Blepharoptosisbr Entered into Share Purchase Agreement with U.S. Ophthalmic Company Eyevance Entered into Long-term Partnership with Orbis International to Tackle the Increasing Burden of Eye Diseases Entered into 10-year partnership agreement with JBFA and IBF Foundation for an Inclusive Society Entered into Exclusive License Agreement with Aerie for Rhopressa and Rocklatan in Japan and Several Other Asian Countries Introduced Eco-Friendly Biomass Plastic Eyedrop Bottles LENTIS Comfort Toric launched in Japan Hyalein®S launched in Japan |
| 2021 | Medium-Term Plan “MTP2025” (PDF: 3.79MB)PDF file.Page will open in a new window. formulated Established “Santen Vision for the Earth 2050”Joined the Valuable 500 International Initiative Promoting the Active Participation of People with Disabilities Joined the “30% Club Japan,” Taking Action to Increase Gender Diversity at Board and Senior Management Signed the “UN Women’s Empowerment Principles” Promoting Gender Equality and Women’s Empowerment in the Workplace, Marketplace and Community Endorsed by the Science Based Targets (SBT) initiative of Santen's CO2 emission reduction targets Took action with IAPB to implement the first ever UN General Assembly resolution recognizing the link between eye health and sustainable development Entered into a New Collaboration with Glaukos in the Development and Commercialization of STN2000100 (DE-128) in the Americas, Australia, and New Zealand Entered into an exclusive licensing agreement with Sydnexis for SYD-101, a novel investigational treatment for progressive childhood myopia Entered into Partnership with Airdoc Improve Diagnostic Rate of Fundus Ocular Diseases with AI device in China Announced a Strategic Partnership with Singapore National Eye Centre to Develop and Deploy Internationally an Innovative Educational Programme for Development of the Eye Care Ecosystem in Asia Entered into a joint development agreement with ActualEyes on Phase II clinical trial (Phase II a / PoC study) for a treatment candidate for Fuchs endothelial corneal dystrophy Accelerated global deployment of Rhopressa/Rhokiinsa and Rocklatan/Roclanda with Aerie Expanding the area of exclusive licensing, including Europe and China Sante FX AL and Sante FX CL launched in Japan Eye drop type eye wash: Well-Wash EYE launched in Japan |
| 2022 | Takeshi Ito is appointed president Completion of Third Building on Site of Shiga Product Supply Center DIQUAS LX Ophthalmic Solution 3% for dry-eye treatment dry-eye treatment launched in Japan Verkazia (Cyclosporine Ophthalmic Emulsion) 0.1% launched in the US Saniodide launched in Japan Certified as Digital Transformation Business Operator by Ministry of Economy, Trade and Industry |
| 2023 | Announced New Medium-Term Management Plan (FY2023-FY2025) Sante Medical Plus series launched in JapanSelected as "The Sustainability Yearbook Member" by S&P Global |
Diquas is the world’s first eye drop to take advantage of the pharmacological action of a P2Y2 receptor agonist. The drug treats dry eye by promoting the secretion of water and mucin, one of the major components of tears, and returning the tear film coating in the eye back to its normal state. Official SNS
